UNSPSC 51313705: Zolamine

This classification denotes a histamine-1 receptor antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NXB79TB0N2. European Medicines Agency schedules Zolamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00173MIG. Zolamine generally arises in the molecular formula C15H21N3OS.

UNSPSC 51313705 Zolamine is a Commodity code that in practice encompasses naloxone, safe drug deactivation systems, and generic multi-source pharmaceuticals and over-the-counter products procured by state health agencies, county health departments, and multistate cooperative purchasing consortia to support community health, emergency response, and pharmacy benefit programs. State and local buyers under this code range from individual county health departments managing direct procurement to statewide health agencies and regional purchasing cooperatives coordinating supply chains across multiple participating jurisdictions. The work being solicited includes competitive bid solicitations for emergency-response pharmaceuticals with specified annual unit volumes and delivery schedules, requests for information to establish direct-to-manufacturer prescription fulfillment channels, and multi-vendor RFPs for generic pharmaceutical and OTC product supply through authorized wholesaler networks. Vendors must typically comply with cGMP and Drug Supply Chain Security Act certification, maintain substantial commercial general liability and professional liability insurance, submit pricing in multiple formats (fixed, net price, WAC-minus), and meet federal compliance requirements including FDA approval, E-Verify, and drug-free workplace certification.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program designed to improve prescription fulfillment efficiency outside traditional PBM and GPO arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP on January 20, 2026, for generic multi-source pharmaceuticals and OTC products serving participating state and local facilities across Minnesota and Oregon, with proposals due March 26, 2026, and contract effectiveness set for July 1, 2026. The MMCAP procurement requires vendors to work through three authorized wholesalers and imposes a 3 percent administrative fee on all contract purchases alongside performance penalties for compliance violations.